TXG
10x Genomics, Inc.
Stock
$93.50+4.74 (+5.34%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | — | — | $393M | $389M | $430M | $587M | $664M | $424M | $65M | $48M |
| Inventory | $53M | $56M | $83M | $74M | $82M | $60M | $30M | $15M | $8.6M | — |
| Current assets | $675M | $684M | $584M | $596M | $635M | $748M | $774M | $481M | $106M | — |
| Goodwill | $6.9M | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M | $0 | — | — | — |
| Intangible assets | $61M | $62M | $16M | $17M | $23M | $25M | $22M | $22M | $642K | — |
| Total assets | $1.0B | $1.0B | $919M | $965M | $1.0B | $1.0B | $929M | $46M | $124M | — |
| Current liabilities | $119M | $153M | $118M | $127M | $131M | $110M | $118M | $63M | $32M | — |
| Long-term debt | — | — | — | — | — | — | $0 | $20M | $25M | — |
| Total liabilities | $205M | $245M | $209M | $224M | $223M | $201M | $190M | $78M | $101M | — |
| Shareholders' equity | $826M | $796M | $710M | $741M | $806M | $818M | $739M | $420M | −$220M | −$113M |
| Shares outstanding | — | 127.7M | 122.3M | 119.1M | 115.2M | 112.5M | 108.5M | 96.2M | — | — |
| Current ratio | 5.69 | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 | 6.56 | 7.63 | 3.28 | — |